NCT01969643 (Clinical Trial / SGN-LIV1A)

Study Title
A Safety Study of SGN-LIV1A in Breast Cancer Patients (NCT01969643)

Trial Description
This study is being conducted to examine the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer, and to find the highest dose of the drug that can be given without unacceptable side effects. Other goals of the trial are to find out if SGN-LIV1A has any antitumor effects, to learn about the pharmacokinetics of SGN-LIV1A, and to explore the relationship between antigen expression and SGN-LIV1A effects.

This trial is sponsored by Seattle Genetics. [1]

Study Data

  • Condition: Breast Cancer
  • Interventions:
    • Drugs used in this trial
      • SGN-LIV1A
  • Phase: I
  • Estimated Enrollment: 216
  • Start: September 2013
  • Estimated Completion: December 2019
  • Last verified: February 2018

Study Schematic


Click here to Return to Drug map

Last Editorial review: February 2018
Information based on (NIH/NCI) and other sources.

Copyright © 2015-2018 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.